Portfolio companies news
-
11 September 2013
Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration(FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.
-
05 September 2013
Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions.
-
29 August 2013
Tragara Completes $12M Series B Financing New Round to Fund Continued Clinical Development of TG02
Tragara Pharmaceuticals, Inc. announced today that it has secured $12 million in the close of a Series B financing. Participating investors included Domain Associates, Mitsubishi International Corporation, Morganthaler Ventures, ProQuest Investments and RusnanoMedInvest (RMI).
-
27 August 2013
Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers, today announced it has secured a $26.6 million Series B financing.
-
30 June 2013
Corneal inlays have the potential to 'treat millions'
Michelle Dalton, EyeWorld
Corneal inlays are designed to treat presbyopia by being inserted in the non-dominant eye and correcting for near vision; distance vision remains (mostly) unaffected.
-
25 June 2013
ReVision Optics: European study shows positive results for inlay in emmetropic presbyopic patients
Results of the EuroKLEAR multicenter showed the safety and efficacy of the ReVision Optics Raindrop aspheric corneal inlay in emmetropic presbyopic patients.
-
04 February 2013
Nanotechnology Didn't Shrink and Disappear; In Fact, It's Everywhere
Nick Rockel, Institutional Investor
Nanotechology, which involves controlling matter at the molecular and atomic levels, was a much-hyped investment theme a decade ago. It’s since become widely used in commercial products ranging from solar panels to semiconductors, but investing in nanotech requires patience.
-
01 February 2013
Tracey Sunderland, COO, Coda Therapeutics Inc: “We think we’ve got something that has the potential to be a real game changer in this space particularly due to the fact that there are no therapeutic compounds on the market currently.”
-
09 January 2013
San Diego Life Sciences Roundup: Trius, CoDa, Zacharon, & More
Bruce V. Bigelow, Xconomy
The annual International CES in Las Vegas again featured a Digital Health Summit, which included a number of San Diego-based startups. Rick Valencia of Qualcomm Life posted an interesting blog here, and an end-of-year report from Rock Health showed that investments in digital health startups increased more than 44 percent in 2012, to $1.4 billion from $968 million in 2011.
-
09 January 2013
CoDa Therapeutics, Inc. today announced positive results from a Phase 2b clinical trial of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. The company believes these results support advancing NEXAGON into Phase 3 registration trials. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.